RECIST 1.1 and Serum Thyroglobulin Measurements in the Evaluation of Responses to Sorafenib in Patients With Radioactive Iodine‑refractory Differentiated Thyroid Carcinoma

Oncology Letters - Greece
doi 10.3892/ol.2013.1424
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications


Related search